Equities

Alliance Pharma PLC

Alliance Pharma PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)46.95
  • Today's Change-0.05 / -0.11%
  • Shares traded619.00k
  • 1 Year change+31.15%
  • Beta0.8112
Data delayed at least 20 minutes, as of Nov 08 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Alliance Pharma PLC had net income fall 56.24% from a loss of 21.21m to a larger loss of 33.14m despite a 7.92% increase in revenues from 167.42m to 180.68m. An increase in the cost of goods sold as a percentage of sales from 39.26% to 41.88% was a component in the falling net income despite rising revenues.
Gross margin59.42%
Net profit margin-18.34%
Operating margin-21.80%
Return on assets-7.36%
Return on equity-13.44%
Return on investment-8.08%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Alliance Pharma PLC fell by 9.28m. However, the company earned 31.41m from its operations for a Cash Flow Margin of 17.38%. In addition the company used 918.00k on investing activities and also paid 39.19m in financing cash flows.
Cash flow per share-0.04
Price/Cash flow per share--
Book value per share0.4124
Tangible book value per share-0.1321
More ▼

Balance sheet in GBPView more

Alliance Pharma PLC has a Debt to Total Capital ratio of 32.18%, a lower figure than the previous year's 44.67%.
Current ratio2.93
Quick ratio2.06
Total debt/total equity0.4746
Total debt/total capital0.3218
More ▼

Growth rates in GBP

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -100.00% and -56.07%, respectively.
Div yield(5 year avg)1.50%
Div growth rate (5 year)--
Payout ratio (TTM)--
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-14.90
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.